Navigation Links
The Lancet Publishes Vasogen's ACCLAIM Results
Date:1/18/2008

MISSISSAUGA, ON, Jan. 18 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that The Lancet, a world-leading medical journal, will publish an article entitled 'Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial' in its January 19th issue (Lancet 2008; 371: 228-36). The article describes the results from Vasogen's 2,400-patient ACCLAIM trial of its Celacade(TM) system in patients with chronic heart failure. Celacade is designed to target the destructive chronic inflammation underlying the development and progression of chronic heart failure.

The interpretation of the findings in The Lancet is that: "Non-specific immunomodulation (Celacade) may have a role as a potential treatment for a large segment of the heart failure population, which includes patients without a history of myocardial infarction (irrespective of their functional NYHA class) and patients within NYHA class II."

While the ACCLAIM study did not meet its primary endpoint for the intent-to treat-population, this primary endpoint was met for two large pre-specified subgroups of patients. In the trial, Celacade was shown to significantly reduce the risk of death or cardiovascular hospitalization by 39% in the subgroup of 689 patients with NYHA Class II heart failure, and by 26% in the subgroup of 919 patients with no prior history of heart attack. Importantly, the large risk reduction observed in these subgroups was achieved on top of the benefits derived from current standard-of-care medications and device therapy for heart failure.

"We are extremely pleased with the publication of the ACCLAIM results in The Lancet," commented Chris Waddick, President a
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
2. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
3. Consortium publishes Phase II map of human genetic variation
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. CNS Response Announces Fiscal Third Quarter 2007 Results
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/16/2013)... 16, 2013 ISPE ... Myers, CAE, to the newly created position of ... role, Myers will be responsible for stimulating ISPE’s ... strategies, advancing the Society’s Member-led and staff-driven business ... to refine organizational, membership and product marketing. , ...
(Date:5/16/2013)... Kitware , a leading provider of ... II SBIR funding from the U.S. Department of ... high performance computing (HPC) simulation and computation framework. ... select only the toolkits and applications needed to ... tasks. , Manufacturers increasingly rely on simulation ...
(Date:5/16/2013)... 16, 2013 On average, developing a ... one billion dollars. Despite this investment, less than 10% ... high, is your clinical trial design optimally structured to ... outcomes? , Dr. Frederic Sax, Global Head of the ... use of data, information and technology in upfront clinical ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... available in German . , Carbon nanotubes ... promising candidates for optoelectronic components. However, so far it ... optic and electronic properties. A team of researchers headed ... Universitaet Muenchen and member of the Cluster of Excellence ...
... 7, 2011 Reportlinker.com announces that a ... its catalogue: http://www.reportlinker.com/p0368623/The-2011-Top-Ten-Worlds-Leading-Life-Science-Intermediates-Companies.html ... the competitive environment is widely recognized as ... the task crucial to business survival, growth ...
... Reportlinker.com announces that a new market research report ... Nanobiotechnologies- applications, markets and companies ... the creation and utilization of materials, devices, and ... nanometer-length scale (a nanometer is one billionth of ...
Cached Biology Technology:Ultra fast photodetectors out of carbon nanotubes 2Reportlinker Adds The 2011 Top Ten World's Leading Life Science Intermediates Companies 2Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 2Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies 3
(Date:5/15/2013)... trial to date to examine the efficacy of PARP ... than breast and ovarian cancer, the oral drug olaparib ... prostate cancers. Results of the study, led by researchers ... of Pennsylvania and Sheba Medical Center in Tel Hashomer, ... Clinical Oncology,s annual meeting in Chicago in early June ...
(Date:5/15/2013)... N.Y. - Clam fossils from the middle Devonian era ... a better paleontological picture of the capacity of ecosystems ... according to research published today (May 15) in the ... examine species abundance the head counts of specimens ... The research shows that factors such as predation and ...
(Date:5/15/2013)... world-renowned filmmaker James Cameron has been named by Scripps ... recipient of the 2013 Nierenberg Prize for Science in ... his record-setting DEEPSEA CHALLENGE expedition and exploration of the ... on the UC San Diego campus. , In addition, ... and promise of the deep sea has been considerably ...
Breaking Biology News(10 mins):PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2Clam fossils divulge secrets of ecologic stability 2James Cameron to be publicly honored with Scripps Nierenberg Prize 2James Cameron to be publicly honored with Scripps Nierenberg Prize 3James Cameron to be publicly honored with Scripps Nierenberg Prize 4
... incandescent light bulb in the 19th century spurred on ... extending leisure time and bringing us to the point ... range of devices from mood lighting to audiovisual media ... vacuum cleaners to high-speed broadband connected computers in their ...
... Finland, has been the first in the world to ... in the treatment of osteoarthritis and rheumatoid arthritis. ... that allows the product to be sold in the ... since the mid-1990s, is the result of collaboration between ...
... This release is available in German . ... component of the Lily of the Valley scent known as Bourgeonal alters ... of the Valley phenomenon" also the title of a book about ... act as swimming olfactory cells which follow a "scent trail" laid by ...
Cached Biology News:Developing sustainable power 2Researchers develop world's first biodegradable joint implant 2The end of the 'Lily of the Valley phenomenon' in sperm research? 2The end of the 'Lily of the Valley phenomenon' in sperm research? 3
... a microprocessor controlled, high speed filter ... exceptionally smooth operation make the Lambda ... fluorescence microscopy, ratio imaging, spectrophotometry, visual ... and accurate aperture positioning. The Lambda ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
... enzyme that catalyzes the conversion,of starch ... maltotriose and,dextrins. The level of a-amylase ... are of clinical importance,1-3 while plant ... industry.4, The EnzChek Amylase Assay Kit ...
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
Biology Products: